285 related articles for article (PubMed ID: 24113254)
21. Intramuscular progesterone in women with twins and a prior singleton spontaneous preterm birth.
Ward A; Greenberg V; Valcarcel B; Boelig RC; Al-Kouatly HB; Berghella V
Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100124. PubMed ID: 33345870
[TBL] [Abstract][Full Text] [Related]
22. Operationalizing 17α-Hydroxyprogesterone Caproate to Prevent Recurrent Preterm Birth: Definitions, Barriers, and Next Steps.
Stringer EM; Vladutiu CJ; Batra P; Stringer JSA; Menard MK
Obstet Gynecol; 2016 Dec; 128(6):1397-1402. PubMed ID: 27824772
[TBL] [Abstract][Full Text] [Related]
23. 17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.
Lim AC; Schuit E; Bloemenkamp K; Bernardus RE; Duvekot JJ; Erwich JJHM; van Eyck J; Groenwold RHH; Hasaart THM; Hummel P; Kars MM; Kwee A; van Oirschot CM; van Pampus MG; Papatsonis D; Porath MM; Spaanderman ME; Willekes C; Wilpshaar J; Mol BWJ; Bruinse HW
Obstet Gynecol; 2011 Sep; 118(3):513-520. PubMed ID: 21860279
[TBL] [Abstract][Full Text] [Related]
24. 17-α Hydroxyprogesterone Caproate for the Prevention of Recurrent Preterm Birth: One Size May Not Fit All.
Heyborne KD
Obstet Gynecol; 2016 Oct; 128(4):899-903. PubMed ID: 27607880
[TBL] [Abstract][Full Text] [Related]
25. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.
O'Brien JM; Lewis DF
Am J Obstet Gynecol; 2016 Jan; 214(1):45-56. PubMed ID: 26558340
[TBL] [Abstract][Full Text] [Related]
26. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17-α hydroxyprogesterone caproate.
Durnwald CP; Momirova V; Rouse DJ; Caritis SN; Peaceman AM; Sciscione A; Varner MW; Malone FD; Mercer BM; Thorp JM; Sorokin Y; Carpenter MW; Lo J; Ramin SM; Harper M; Spong CY;
J Matern Fetal Neonatal Med; 2010 Dec; 23(12):1360-4. PubMed ID: 20441408
[TBL] [Abstract][Full Text] [Related]
27. 17 α-Hydroxyprogesterone caproate (Makena™): in the prevention of preterm birth.
Deeks ED
Paediatr Drugs; 2011 Oct; 13(5):337-45. PubMed ID: 21888448
[TBL] [Abstract][Full Text] [Related]
28. 17α Hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
Merlob P; Stahl B; Klinger G
Reprod Toxicol; 2012 Jan; 33(1):15-9. PubMed ID: 22120850
[TBL] [Abstract][Full Text] [Related]
29. A Possible Mechanism of Action of 17α-Hydroxyprogesterone Caproate: Enhanced IL-10 Production.
Megli CJ; Hauspurg A; Venkataramanan R; Caritis SN
Am J Perinatol; 2023 Oct; 40(14):1585-1589. PubMed ID: 34784615
[TBL] [Abstract][Full Text] [Related]
30. Racial and ethnic disparities in use of 17-alpha hydroxyprogesterone caproate for prevention of preterm birth.
Yee LM; Liu LY; Sakowicz A; Bolden JR; Miller ES
Am J Obstet Gynecol; 2016 Mar; 214(3):374.e1-6. PubMed ID: 26829989
[TBL] [Abstract][Full Text] [Related]
31. Understanding barriers to uptake of 17 alpha-hydroxyprogesterone caproate (17-OHP) in women with history of preterm birth.
Kalata M; Teter K; Wagner L; Swarr V; Witzeman K
J Matern Fetal Neonatal Med; 2021 Feb; 34(4):541-546. PubMed ID: 31006296
[No Abstract] [Full Text] [Related]
32. 17α-Hydroxyprogesterone Caproate and the Risk of Glucose Intolerance in Pregnancy: A Systematic Review and Meta-analysis.
Eke AC; Sheffield J; Graham EM
Obstet Gynecol; 2019 Mar; 133(3):468-475. PubMed ID: 30741815
[TBL] [Abstract][Full Text] [Related]
33. 17 α-hydroxyprogesterone caproate (Makena®): a guide to its use in the prevention of preterm birth.
Hines M; Lyseng-Williamson KA; Deeks ED
Clin Drug Investig; 2013 Mar; 33(3):223-7. PubMed ID: 23413110
[TBL] [Abstract][Full Text] [Related]
34. Preventing recurrent preterm birth with 125 mg of 17-alpha-hydroxyprogesterone caproate.
Fukuda T; Kyozuka H; Murata T; Yasuda S; Yamaguchi A; Fujimori K
J Obstet Gynaecol Res; 2021 Sep; 47(9):3119-3126. PubMed ID: 34219326
[TBL] [Abstract][Full Text] [Related]
35. Progestogens in singleton gestations with preterm prelabor rupture of membranes: a systematic review and metaanalysis of randomized controlled trials.
Quist-Nelson J; Parker P; Mokhtari N; Di Sarno R; Saccone G; Berghella V
Am J Obstet Gynecol; 2018 Oct; 219(4):346-355.e2. PubMed ID: 29614278
[TBL] [Abstract][Full Text] [Related]
36. Spontaneous preterm birth in African-American and Caucasian women receiving 17α-hydroxyprogesterone caproate.
Timofeev J; Singh J; Istwan N; Rhea D; Driggers RW
Am J Perinatol; 2014 Jan; 31(1):55-60. PubMed ID: 23456908
[TBL] [Abstract][Full Text] [Related]
37. 17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going?
Manuck TA
Semin Perinatol; 2017 Dec; 41(8):461-467. PubMed ID: 28947068
[TBL] [Abstract][Full Text] [Related]
38. Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations.
Feghali M; Venkataramanan R; Caritis S
Semin Perinatol; 2014 Dec; 38(8):516-22. PubMed ID: 25256193
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant 17-hydroxyprogesterone caproate in women withultrasound-indicated cerclage: a systematic review and meta-analysis.
Lichter KE; Sheffield J; Graham EM; Eke AC
J Matern Fetal Neonatal Med; 2020 Sep; 33(18):3177-3184. PubMed ID: 30626240
[No Abstract] [Full Text] [Related]
40. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States.
Petrini JR; Callaghan WM; Klebanoff M; Green NS; Lackritz EM; Howse JL; Schwarz RH; Damus K
Obstet Gynecol; 2005 Feb; 105(2):267-72. PubMed ID: 15684150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
